Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option
October 02 2018 - 3:05PM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced the closing of its underwritten public
offering of 4,600,000 American Depositary Shares (“ADSs”)
representing 4,600,000 ordinary shares, at a public offering price
of $18.00 per ADS, which includes the exercise in full by the
underwriters of their option to purchase up to an additional
600,000 ADSs. The aggregate gross proceeds to Nightstar from the
offering were $82.8 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Nightstar. All ADSs sold in the offering were offered by
Nightstar.
Jefferies LLC, Barclays Capital Inc. and UBS Investment Bank are
acting as joint book-running managers for the offering. Wedbush
Securities Inc. and Chardan are acting as co-managers.
The offering was made only by means of a prospectus. Copies of
the final prospectus may be obtained from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail:
Prospectus_Department@Jefferies.com; or Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: (888) 603-5847, e-mail:
barclaysprospectus@broadridge.com; or UBS Securities LLC,
Attention: Prospectus Department, 1285 Avenue of the Americas, New
York, NY 10019, telephone: (888) 827-7275, email:
olprospectusrequest@ubs.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Nightstar
Nightstar is a leading clinical-stage gene
therapy company focused on developing and commercializing novel
one-time treatments for patients suffering from rare inherited
retinal diseases that would otherwise progress to blindness.
Cautionary Language Concerning Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. The words “believe,” “anticipate,” “could,” “intend,”
“estimate,” “will,” “would,” “may,” “should,” “project,” “target,”
“track,” “expect” or other similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. All
statements contained in this press release other than statements of
historical facts are forward-looking statements, including, without
limitation: the anticipated use of proceeds from the offering; our
planned and ongoing clinical development for NSR-REP1 and NSR-RPGR,
including our Phase 3 STAR trial in choroideremia and Phase 1/2
XIRIUS trial in X-linked retinitis pigmentosa; the continued
clinical development of our pipeline; and statements about our cash
position and sufficiency of capital resources to fund our operating
requirements, trends and other factors that may affect our
financial results. These forward-looking statements are based on
management's current expectations of future events as of the date
of this release and are subject to a number of substantial known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements, including those
related to the timing and costs involved in commercializing any
product candidate that receives regulatory approval; the
initiation, timing and conduct of clinical trials; the availability
of data from clinical trials and expectations for regulatory
submissions and approvals; whether interim results of a clinical
trial will be predictive of the final results of the trial; whether
results of small or early stage clinical trials will be predictive
of the results of later-stage trials; our scientific approach and
general development progress; the availability or commercial
potential of the our product candidates; the sufficiency of our
cash resources; and other risks and uncertainties set forth in our
Report of Foreign Private Issuer on Form 6-K furnished to the U.S.
Securities and Exchange Commission on September 25, 2018 and
subsequent reports that we file with the U.S. Securities and
Exchange Commission. We may not actually achieve the plans,
intentions, estimates or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions, estimates and
expectations disclosed in the forward-looking statements we make.
We anticipate that subsequent events and developments will cause
our views to change. We are under no duty to update any of these
forward-looking statements after the date of this press release to
conform these statements to actual results or revised expectations,
except as required by law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release. Any reference to our
website address in this press release is intended to be an inactive
textual reference only and not an active hyperlink.
Contact:Senthil Sundaram, Chief Financial
OfficerBrian Luque, Sr. Manager, Investor
Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2024 to May 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From May 2023 to May 2024